Table 1.
Summary of cases with EGFR-mutated NSCLC with SCLC transformation after the cessation of EGFR-TKI therapy.
| Cases | Age | Sex | Primary EGFR mutation | Primary TKI (duration) | Treatment after primary TKI | Duration from final TKI to SCLC transformation (months) |
|---|---|---|---|---|---|---|
| Previously reported cases | ||||||
| Sequist LV et al. [3] | 40 | F | Ex. 19 del | erlotinib (more than 2 years) | NAa | 2 |
| van Riel S et al. [13] | 42 | F | NAa | erlotinib (10 months) | CBDCA + PTX, erlotinib, DTX | 2 |
| Zakowski MF et al. [9] | 45 | F | NAa | erlotinib (18 months) | mitomycin + vinblastine | 2 |
| Morinaga R et al. [12] | 46 | F | Ex. 19 del | gefitinib (10 months) | NAa | 5 |
| Yang MH et al. [15] | 50 | M | Ex. 19 del | erlotinib (6.5 months) | CBDCA + PTX + toripalimab | 6.6 |
| Popat S et al. [11] | 46 | F | Ex. 19 del | erlotinib (12 months) | CDDP + PEM, thoracic radiotherapy | 7 |
| Otoshi R et al. [14] | 68 | M | Ex. 19 del | osimertinib (11 months) | Erlotinib, CBDCA + PTX,DTX, PEM, S-1 | 19 |
| Our cases | ||||||
| Case 1 | 26 | F | Ex. 19 del | afatinib (8 months) | CDDP + PEM + Bev, DTX + RAM,S-1, afatinib, GEM, osimertinib, nab-PTX, AMR | 10 |
| Case 2 | 67 | M | Ex. 19 del | gefitinib (10 months) | osimertinib, CBDCA + PEM,DTX | 8 |
| Case 3 | 70 | F | Ex. 19 del | osimertinib (24 months) | CBDCA + PEM, DTX + RAM | 8 |
a
NA, not available; EGFR, epidermal growth factor receptor; NSCLC, non-small-cell lung cancer; SCLC, small-cell lung cancer; TKI, tyrosine kinase inhibitor; Ex. 19 del, exon 19 deletion; CBDCA, carboplatin; PTX, paclitaxel; DTX, docetaxel; CDDP, cisplatin; PEM, pemetrexed; S-1, tegafur-gimeracil-oteracil potassium; Bev, bevacizumab; RAM, ramucirumab; GEM, gemcitabine; nab-PTX, nanoparticle albumin bound-paclitaxel; AMR, amrubicin.